What is ENDRA Life Sciences Debt-to-Equity?
ENDRA Life Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.20 Mil. ENDRA Life Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.19 Mil. ENDRA Life Sciences's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $5.66 Mil.
ENDRA Life Sciences's debt to equity for the quarter that ended in Dec. 2023 was 0.07.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for ENDRA Life Sciences's Debt-to-Equity or its related term are showing as below:
NDRA'
s Debt-to-Equity Range Over the Past 10 Years
Min: -1.06 Med: 0.07 Max: 0.15
Current: 0.07
During the past 10 years, the highest Debt-to-Equity Ratio of ENDRA Life Sciences was 0.15. The lowest was -1.06. And the median was 0.07.
ENDRA Life Sciences Debt-to-Equity Historical Data
The historical data trend for ENDRA Life Sciences's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ENDRA Life Sciences Debt-to-Equity Chart
|
ENDRA Life Sciences Annual Data
|
|
Trend |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Debt-to-Equity |
|
Get a 7-Day Free Trial
|
|
|
0.15 |
0.10 |
0.06 |
0.08 |
0.07 |
|
ENDRA Life Sciences Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Debt-to-Equity |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
0.08 |
0.11 |
0.07 |
0.08 |
0.07 |
Competitive Comparison of ENDRA Life Sciences's Debt-to-Equity
For the Diagnostics & Research subindustry, ENDRA Life Sciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ENDRA Life Sciences's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, ENDRA Life Sciences's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where ENDRA Life Sciences's Debt-to-Equity falls into.
ENDRA Life Sciences Debt-to-Equity Calculation
Debt to Equity measures the financial leverage a company has.
ENDRA Life Sciences's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as
ENDRA Life Sciences's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ENDRA Life Sciences (ENDRA Life Sciences) Business Description
Traded in Other Exchanges
N/A
Address
3600 Green Court, Suite 350, Ann Arbor, MI, USA, 48105-1570
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI but at 1/50th the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.
Executives
| Michael Milos Thornton |
officer: Chief Technology Officer |
3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105 |
| Anthony Digiandomenico |
director |
3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105 |
| Alexander Y Tokman |
director |
C/O MICROVISION, INC., 6222 185TH AVENUE NE, REDMOND WA 98052 |
| Francois Roger Michelon |
director, officer: Chief Executive Officer |
430 N. JUNO LANE, JUNO BEACH FL 33406 |
| Lou Basenese |
director |
3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105 |
| Irina Pestrikova |
officer: Senior Director, Finance |
3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105 |
| Renaud Bertrand Maloberti |
officer: Chief Commercial Officer |
10 ACORN WAY, GEORGETOWN MA 01833 |
| David R. Wells |
officer: Chief Financial Officer |
2801 OCEAN PARK BLVD., SUITE 339, SANTA MONICA CA 90405 |
| Michael Harsh |
director |
3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105 |
| Longboard Capital Advisors, Llc |
10 percent owner |
9665 WILSHIRE BLVD., SUITE 430, BEVERLY HILLS CA 90212 |
| Brett Conrad |
10 percent owner |
1312 CEDAR ST., SANTA MONICA CA 90405 |
| Sanjiv Sam Gambhir |
director |
3600 GREEN COURT, SUITE 350, ANN ARBOR MI 48105 |
ENDRA Life Sciences (ENDRA Life Sciences) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NDRA has been successfully added to your